These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 33514507)

  • 1. Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study.
    Yoon D; Lee JH; Lee H; Shin JY
    BMJ; 2021 Jan; 372():m4931. PubMed ID: 33514507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system.
    Scheller NM; Svanström H; Pasternak B; Arnheim-Dahlström L; Sundström K; Fink K; Hviid A
    JAMA; 2015 Jan; 313(1):54-61. PubMed ID: 25562266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study.
    Arnheim-Dahlström L; Pasternak B; Svanström H; Sparén P; Hviid A
    BMJ; 2013 Oct; 347():f5906. PubMed ID: 24108159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases.
    Hviid A; Svanström H; Scheller NM; Grönlund O; Pasternak B; Arnheim-Dahlström L
    J Intern Med; 2018 Feb; 283(2):154-165. PubMed ID: 29044769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).
    Eun BW; Bahar E; Xavier S; Kim H; Borys D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2184756. PubMed ID: 36896702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 10 Years After Approval.
    Martín-Merino E; Llorente-García A; Castillo Cano B; Montero Corominas D; Huerta-Álvarez C
    Pharmaceut Med; 2019 Dec; 33(6):519-530. PubMed ID: 31933243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
    Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
    Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland.
    Skufca J; Ollgren J; Artama M; Ruokokoski E; Nohynek H; Palmu AA
    Vaccine; 2018 Sep; 36(39):5926-5933. PubMed ID: 30115524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
    Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
    Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort.
    Hviid A; Myrup Thiesson E
    JAMA Netw Open; 2021 Aug; 4(8):e2120391. PubMed ID: 34436612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12-15 years: end-of-study results from a community-randomized study up to 6.5 years.
    Bi D; Apter D; Eriksson T; Hokkanen M; Zima J; Damaso S; Soila M; Dubin G; Lehtinen M; Struyf F
    Hum Vaccin Immunother; 2020 Jun; 16(6):1392-1403. PubMed ID: 31829767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events from HPV vaccination in Taiwan.
    Tsai SA; Lu CY; Chen TI; Huang SP; Chen YC
    Vaccine; 2023 Nov; 41(49):7444-7449. PubMed ID: 37949754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous preterm birth risk among HPV-vaccinated and -unvaccinated women: a nationwide retrospective cohort study of over 240 000 singleton births.
    McClymont E; Faber MT; Belmonte F; Kjaer SK
    BJOG; 2023 Mar; 130(4):358-365. PubMed ID: 36424904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus-16/18 Vaccine in Four- to Six-year-old Girls: Three-year Follow-up of a Randomized Phase III Trial.
    Lin L; Macias Parra M; Sierra VY; Salas Cespedes A; Granados MA; Luque A; Karkada N; Castrejon Alba MM; Romano-Mazzotti L; Borys D; Struyf F
    Pediatr Infect Dis J; 2019 Oct; 38(10):1061-1067. PubMed ID: 31469776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer.
    Kjaer SK; Dehlendorff C; Belmonte F; Baandrup L
    J Natl Cancer Inst; 2021 Oct; 113(10):1329-1335. PubMed ID: 33876216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.
    Lehtinen M; Eriksson T; Apter D; Hokkanen M; Natunen K; Paavonen J; Pukkala E; Angelo MG; Zima J; David MP; Datta S; Bi D; Struyf F; Dubin G
    Hum Vaccin Immunother; 2016 Dec; 12(12):3177-3185. PubMed ID: 27841725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections in temporal proximity to HPV vaccination and adverse effects following vaccination in Denmark: A nationwide register-based cohort study and case-crossover analysis.
    Krogsgaard LW; Petersen I; Plana-Ripoll O; Bech BH; Lützen TH; Thomsen RW; Rytter D
    PLoS Med; 2021 Sep; 18(9):e1003768. PubMed ID: 34495975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands.
    Schurink-Van't Klooster TM; de Ridder MA; Kemmeren JM; van der Lei J; Dekker F; Sturkenboom M; de Melker HE
    Eur J Pediatr; 2015 May; 174(5):641-9. PubMed ID: 25367054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence found for an increased risk of long-term fatigue following human papillomavirus vaccination of adolescent girls.
    Schurink-Van't Klooster TM; Kemmeren JM; van der Maas NAT; van de Putte EM; Ter Wolbeek M; Nijhof SL; Vanrolleghem AM; van Vliet JA; Sturkenboom M; de Melker HE
    Vaccine; 2018 Oct; 36(45):6796-6802. PubMed ID: 30262246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.